Biomarin Pharmaceuticals (BMRN)

$61.44 -1.18 (-1.88%)
Market Cap 12.03B
Revenue (ttm) 2.85B
Net Income (ttm) 426.86M
EPS (ttm) N/A
PE Ratio 25.89
Forward PE 13.82
Profit Margin 14.96%
Debt to Equity Ratio 0.00
Volume 1,881,900
Avg Vol 2,582,394
Day's Range N/A - N/A
Shares Out 192.11M
Stochastic %K 43%
Beta 0.26
Analysts Strong Sell
Price Target $88.73

Company Profile

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic pep...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 506 6700
Address:
770 Lindaro Street, San Rafael, United States
erevnon
erevnon Feb. 25 at 6:24 PM
Bernstein maintains BioMarin Pharmaceutical $BMRN at Outperform and raises the price target from $90 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Artfldgr
Artfldgr Feb. 24 at 9:29 PM
$PLX $SGMO $BMRN SGMO isn’t a near-term threat because gene therapy in Fabry has three hard problems that haven’t been solved reliably: durability (expression can fade), safety (liver/off-target risks and immune events), and immunity/redosing (many patients can’t be re-dosed). In a disease with approved ERTs, regulators will demand Phase 3 plus long follow-up, so “cure” is a long way from commercial reality.
6 · Reply
1GreenDay99RedDays
1GreenDay99RedDays Feb. 24 at 7:23 PM
$PLX $SGMO has a cure for Fabry, $BMRN has AMICUS' treatment for those who won't need gene therapy, not much need for Protalix Fabry
3 · Reply
ZacksResearch
ZacksResearch Feb. 24 at 6:10 PM
$BMRN beats… then pulls a flagship therapy? 🤔 Big quarter, bigger pivot. BioMarin topped Q4 earnings estimates, with Voxzogo driving year-over-year revenue growth — but management is voluntarily withdrawing its hemophilia gene therapy Roctavian from the market. Strong execution on one front, strategic reset on another. Is this a smart capital allocation move or a red flag? Get the full breakdown 👉 https://www.zacks.com/stock/news/2874477/bmrn-beats-on-q4-earnings-to-withdraw-roctavian-from-market?cid=sm-stocktwits-2-2874477-teaser-34951&ADID=SYND_STOCKTWITS_TWEET_2_2874477_TEASER_34951
0 · Reply
ZacksResearch
ZacksResearch Feb. 24 at 5:10 PM
$BMRN beats Q4 estimates, but why did shares drop? 🤔 📉 Despite a 17% revenue jump driven by Voxzogo, shares fell 2.6% in after-hours trading due to a $119.2M inventory write-off from pulling Roctavian, weighing on investor sentiment. 📊 The stock has increased 7.6% in the past six months, compared with the industry’s 22.9% growth. Full earnings breakdown here 👉 https://www.zacks.com/stock/news/2874477/bmrn-beats-on-q4-earnings-to-withdraw-roctavian-from-market?cid=sm-stocktwits-2-2874477-body-34950&ADID=SYND_STOCKTWITS_TWEET_2_2874477_BODY_34950
0 · Reply
Ohzipit
Ohzipit Feb. 24 at 2:04 PM
$BMRN RJ update post earnings. Fulsome 2026 Catalyst Flow Should More Than Offset Tepid FY26 Voxzogo Guidance. Remains Outperform base case price target $100.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Feb. 24 at 12:14 AM
$BMRN only wack thing about riding pdufa dates is earnings
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 23 at 9:16 PM
$BMRN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.24 down -136.36% YoY • Reported revenue of $874.57M up 17.03% YoY • BioMarin Pharmaceutical Inc. anticipates 2026 total revenues of $3.33B to $3.43B, excluding Amicus contributions. Non-GAAP diluted EPS is projected to be $4.95 to $5.15, with Non-GAAP Operating Margin expected around 40%.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 23 at 9:16 PM
$BMRN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.24 down -136.36% YoY • Reported revenue of $874.57M up 17.03% YoY • BioMarin projects 2026 Total Revenues between $3.33B and $3.43B, with Non-GAAP Diluted EPS expected from $4.95 to $5.15. BioMarin also anticipates a Non-GAAP Operating Margin of approximately 40% for the full year.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 23 at 9:16 PM
$BMRN
0 · Reply
Latest News on BMRN
BioMarin to Participate in Four Upcoming Investor Conferences in March

Feb 24, 2026, 9:00 AM EST - 1 day ago

BioMarin to Participate in Four Upcoming Investor Conferences in March

BioMarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings Call Transcript

Feb 23, 2026, 11:14 PM EST - 2 days ago

BioMarin Pharmaceutical Inc. (BMRN) Q4 2025 Earnings Call Transcript

BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results

Feb 23, 2026, 4:05 PM EST - 2 days ago

BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results

BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET

Feb 17, 2026, 9:00 AM EST - 8 days ago

BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET

BioMarin Announces Closing of Private Offering of Senior Notes

Feb 12, 2026, 4:05 PM EST - 13 days ago

BioMarin Announces Closing of Private Offering of Senior Notes

The Right Play On BioMarin Pharmaceuticals

Feb 1, 2026, 6:17 AM EST - 24 days ago

The Right Play On BioMarin Pharmaceuticals

BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility

Jan 29, 2026, 4:05 PM EST - 27 days ago

BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility

BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility

Jan 26, 2026, 7:45 AM EST - 4 weeks ago

BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility

BioMarin Pharmaceutical Inc. (BMRN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 6:25 PM EST - 6 weeks ago

BioMarin Pharmaceutical Inc. (BMRN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

BioMarin Appoints Arpit Davé Chief Digital and Information Officer

Jan 12, 2026, 4:05 PM EST - 6 weeks ago

BioMarin Appoints Arpit Davé Chief Digital and Information Officer

BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA

Jan 8, 2026, 4:05 PM EST - 6 weeks ago

BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA

Veeva and BioMarin Form Long-Term Strategic Partnership

Jan 8, 2026, 8:30 AM EST - 6 weeks ago

Veeva and BioMarin Form Long-Term Strategic Partnership

VEEV

Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD

Dec 26, 2025, 3:28 PM EST - 2 months ago

Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD

FOLD

What's Going On With BioMarin Stock On Tuesday?

Dec 23, 2025, 1:05 PM EST - 2 months ago

What's Going On With BioMarin Stock On Tuesday?

BioMarin: Amicus Buyout Sparks My Enthusiasm

Dec 22, 2025, 3:15 PM EST - 2 months ago

BioMarin: Amicus Buyout Sparks My Enthusiasm

FOLD

BioMarin Pharmaceutical Inc. (BMRN) M&A Call Transcript

Dec 19, 2025, 11:27 AM EST - 2 months ago

BioMarin Pharmaceutical Inc. (BMRN) M&A Call Transcript

BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.

Dec 19, 2025, 10:55 AM EST - 2 months ago

BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.

FOLD

BioMarin to Buy Amicus Therapeutics for $4.8 Billion

Dec 19, 2025, 8:13 AM EST - 2 months ago

BioMarin to Buy Amicus Therapeutics for $4.8 Billion

FOLD

BioMarin to acquire Amicus Therapeutics for $4.8 Billion

Dec 19, 2025, 7:56 AM EST - 2 months ago

BioMarin to acquire Amicus Therapeutics for $4.8 Billion

FOLD

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

Dec 19, 2025, 7:45 AM EST - 2 months ago

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

FOLD

BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 18, 2025, 9:08 AM EST - 3 months ago

BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies London Healthcare Conference 2025 Transcript

BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England

Nov 11, 2025, 9:00 AM EST - 3 months ago

BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England

FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria

Oct 29, 2025, 9:00 AM EDT - 4 months ago

FDA Accepts BioMarin's PALYNZIQ® (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria

Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings

Oct 28, 2025, 9:48 AM EDT - 4 months ago

Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings

BioMarin Pharmaceuticals - Growing Numbers, Falling Expectations

Oct 28, 2025, 6:58 AM EDT - 4 months ago

BioMarin Pharmaceuticals - Growing Numbers, Falling Expectations

BioMarin Pharmaceutical Inc. (BMRN) Q3 2025 Earnings Call Transcript

Oct 27, 2025, 8:17 PM EDT - 4 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q3 2025 Earnings Call Transcript

BioMarin Pharma plans to divest struggling gene therapy

Oct 27, 2025, 6:34 PM EDT - 4 months ago

BioMarin Pharma plans to divest struggling gene therapy

BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update

Oct 27, 2025, 4:03 PM EDT - 4 months ago

BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update

BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET

Oct 22, 2025, 4:05 PM EDT - 4 months ago

BioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET

BioMarin: Valuation, Growth, And The Pipeline May Outweigh TransCon Competition And Regulatory Risks

Sep 30, 2025, 7:01 AM EDT - 5 months ago

BioMarin: Valuation, Growth, And The Pipeline May Outweigh TransCon Competition And Regulatory Risks

BioMarin Pharmaceutical Inc. (BMRN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 4:46 PM EDT - 6 months ago

BioMarin Pharmaceutical Inc. (BMRN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment

Sep 8, 2025, 1:56 PM EDT - 6 months ago

PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment

PTCT

BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting

Sep 8, 2025, 9:00 AM EDT - 6 months ago

BioMarin Shares New Data Reinforcing Its Leadership in Bone Health at the American Society for Bone and Mineral Research Annual Meeting

BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism

Sep 6, 2025, 11:05 AM EDT - 6 months ago

BioMarin Announces Positive Pivotal Phase 3 Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria at 15th International Congress of Inborn Errors of Metabolism

BioMarin Pharmaceutical Inc. (BMRN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Sep 4, 2025, 11:27 AM EDT - 6 months ago

BioMarin Pharmaceutical Inc. (BMRN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Sep 3, 2025, 3:32 PM EDT - 6 months ago

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

ARGX BBH CYTK IBB XBI

BioMarin Pharmaceutical Inc. (BMRN) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 3, 2025, 11:01 AM EDT - 6 months ago

BioMarin Pharmaceutical Inc. (BMRN) Presents At Cantor Global Healthcare Conference 2025 Transcript

BioMarin to Participate in Upcoming Investor Conferences

Aug 27, 2025, 9:00 AM EDT - 6 months ago

BioMarin to Participate in Upcoming Investor Conferences

BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401

Aug 5, 2025, 4:20 PM EDT - 7 months ago

BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401

INZY

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

Aug 5, 2025, 1:11 PM EDT - 7 months ago

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 11:04 PM EDT - 7 months ago

BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Call Transcript

BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS

Aug 4, 2025, 4:02 PM EDT - 7 months ago

BioMarin Reports Strong Second Quarter 2025 Results and Raises Full-year Guidance¹ for Total Revenues, Non-GAAP Operating Margin, and Non-GAAP Diluted EPS

BioMarin Announces Appointment of Ian T. Clark to Board of Directors

Aug 1, 2025, 9:00 AM EDT - 7 months ago

BioMarin Announces Appointment of Ian T. Clark to Board of Directors

BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET

Jul 22, 2025, 9:00 AM EDT - 7 months ago

BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET

It is time for a move higher in biotech, says Mizuho's Jared Holz

Jul 7, 2025, 6:29 PM EDT - 8 months ago

It is time for a move higher in biotech, says Mizuho's Jared Holz

BBIO GILD INSM XBI

BioMarin Announces Completion of Acquisition of Inozyme

Jul 1, 2025, 8:45 AM EDT - 8 months ago

BioMarin Announces Completion of Acquisition of Inozyme

INZY

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

Jun 24, 2025, 9:00 AM EDT - 8 months ago

BioMarin Presents Five-Year Phase 3 Results Reinforcing Long-Term Efficacy and Safety of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2025 Congress

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

May 21, 2025, 5:56 PM EDT - 10 months ago

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

INZY

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

May 16, 2025, 7:30 AM EDT - 10 months ago

BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma

INZY

BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

May 12, 2025, 9:05 AM EDT - 10 months ago

BioMarin Presents New Data for VOXZOGO® (vosoritide) in Children with Achondroplasia and Other Skeletal Conditions at Two International Endocrinology Meetings

erevnon
erevnon Feb. 25 at 6:24 PM
Bernstein maintains BioMarin Pharmaceutical $BMRN at Outperform and raises the price target from $90 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Artfldgr
Artfldgr Feb. 24 at 9:29 PM
$PLX $SGMO $BMRN SGMO isn’t a near-term threat because gene therapy in Fabry has three hard problems that haven’t been solved reliably: durability (expression can fade), safety (liver/off-target risks and immune events), and immunity/redosing (many patients can’t be re-dosed). In a disease with approved ERTs, regulators will demand Phase 3 plus long follow-up, so “cure” is a long way from commercial reality.
6 · Reply
1GreenDay99RedDays
1GreenDay99RedDays Feb. 24 at 7:23 PM
$PLX $SGMO has a cure for Fabry, $BMRN has AMICUS' treatment for those who won't need gene therapy, not much need for Protalix Fabry
3 · Reply
ZacksResearch
ZacksResearch Feb. 24 at 6:10 PM
$BMRN beats… then pulls a flagship therapy? 🤔 Big quarter, bigger pivot. BioMarin topped Q4 earnings estimates, with Voxzogo driving year-over-year revenue growth — but management is voluntarily withdrawing its hemophilia gene therapy Roctavian from the market. Strong execution on one front, strategic reset on another. Is this a smart capital allocation move or a red flag? Get the full breakdown 👉 https://www.zacks.com/stock/news/2874477/bmrn-beats-on-q4-earnings-to-withdraw-roctavian-from-market?cid=sm-stocktwits-2-2874477-teaser-34951&ADID=SYND_STOCKTWITS_TWEET_2_2874477_TEASER_34951
0 · Reply
ZacksResearch
ZacksResearch Feb. 24 at 5:10 PM
$BMRN beats Q4 estimates, but why did shares drop? 🤔 📉 Despite a 17% revenue jump driven by Voxzogo, shares fell 2.6% in after-hours trading due to a $119.2M inventory write-off from pulling Roctavian, weighing on investor sentiment. 📊 The stock has increased 7.6% in the past six months, compared with the industry’s 22.9% growth. Full earnings breakdown here 👉 https://www.zacks.com/stock/news/2874477/bmrn-beats-on-q4-earnings-to-withdraw-roctavian-from-market?cid=sm-stocktwits-2-2874477-body-34950&ADID=SYND_STOCKTWITS_TWEET_2_2874477_BODY_34950
0 · Reply
Ohzipit
Ohzipit Feb. 24 at 2:04 PM
$BMRN RJ update post earnings. Fulsome 2026 Catalyst Flow Should More Than Offset Tepid FY26 Voxzogo Guidance. Remains Outperform base case price target $100.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Feb. 24 at 12:14 AM
$BMRN only wack thing about riding pdufa dates is earnings
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 23 at 9:16 PM
$BMRN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.24 down -136.36% YoY • Reported revenue of $874.57M up 17.03% YoY • BioMarin Pharmaceutical Inc. anticipates 2026 total revenues of $3.33B to $3.43B, excluding Amicus contributions. Non-GAAP diluted EPS is projected to be $4.95 to $5.15, with Non-GAAP Operating Margin expected around 40%.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Feb. 23 at 9:16 PM
$BMRN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.24 down -136.36% YoY • Reported revenue of $874.57M up 17.03% YoY • BioMarin projects 2026 Total Revenues between $3.33B and $3.43B, with Non-GAAP Diluted EPS expected from $4.95 to $5.15. BioMarin also anticipates a Non-GAAP Operating Margin of approximately 40% for the full year.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 23 at 9:16 PM
$BMRN
0 · Reply
StockBraker
StockBraker Feb. 23 at 9:10 PM
$BMRN
1 · Reply
StockBraker
StockBraker Feb. 23 at 9:01 PM
$BMRN Waiting for results to post. Should be any minute now. https://investors.biomarin.com/financials/quarterly-results/default.aspx
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 23 at 8:48 PM
$RARE $CRSP $NTLA $BMRN $BBIO
0 · Reply
Dennis123x
Dennis123x Feb. 23 at 7:05 PM
$BMRN I'm bullish, but I sold at 65 this morning. Think 70s, but don't want to give back recent gains if there's some issue with the merger.
0 · Reply
Dennis123x
Dennis123x Feb. 23 at 6:31 PM
$BMRN 70 plus after ER.
0 · Reply
snash
snash Feb. 23 at 5:45 PM
$BMRN $50 lotto Puts
0 · Reply
ZacksResearch
ZacksResearch Feb. 23 at 4:40 PM
$FOLD's 91.7% rally in 6 months compared to the industry’s 22.8% rise — is it time to cash in? 🚀💰 Despite missing EPS estimates by 3 cents, revenue surged 24% YoY on a reported basis, beating expectations at $185.2M, thanks to strong sales from Galafold and Pombiliti + Opfolda. Now, a $4.8B acquisition by $BMRN looms for Q2 2026. Discover the full story here 👉 https://www.zacks.com/stock/news/2873684/amicus-q4-earnings-miss-higher-product-sales-drive-yy-revenues?cid=sm-stocktwits-2-2873684-body-34708&ADID=SYND_STOCKTWITS_TWEET_2_2873684_BODY_34708
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Feb. 23 at 12:43 PM
$BMRN $ETON ETON 1.5 more days to get in before pdufa BMRN we got 3 days!
2 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Feb. 20 at 11:31 PM
$BMRN
1 · Reply
Ohzipit
Ohzipit Feb. 20 at 9:44 PM
$BMRN Raymond James has rated outperform with $100 price target!
0 · Reply
IN0V8
IN0V8 Feb. 20 at 9:01 PM
$BMRN Buy Canaccord Genuity raises target to $98 from $84 Canaccord Genuity raises to buy from hold Leerink Partners raises target to $62 from $60
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Feb. 20 at 8:38 PM
$BMRN close above $63.80 babyyyy
0 · Reply